# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contrac...
RBC Capital analyst Mark Mahaney upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Perform to Outperform and raises the pri...
Barclays analyst Stephanie Davis maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from ...
Raymond James analyst John Ransom upgrades GoodRx Holdings (NASDAQ:GDRX) from Market Perform to Outperform and announces $10...
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $14 to $16.
GoodRX shares surged nearly 10% Wednesday afternoon following the announcement of a new direct contracting agreement with Kroge...